Influenza Vaccine Study Will Test the Vaccine’s Safety and Ability to Generate an Immune Response
Vaccine experts at the University of Maryland School of Medicine (UMSOM) have begun multiple clinical trials of vaccines designed to protect against H7N9, an avian influenza virus that was first reported in humans in 2013 in China.
“This research will help us better understand immune responses to the vaccine,” said Wilbur Chen, MD, Associate Professor of Medicine and Chief of the Adult Clinical Studies section in UMSOM’s Center for Vaccine Development (CVD), who is leading one of the trials. “Pandemic preparedness is a priority. While the H7N9 virus is not circulating in the United States at this time, this important research will help us better understand how to protect individuals from the H7N9 influenza strain should it spread outside China.”
CVD has a Vaccine and Treatment Evaluation Unit (VTEU) funded by the National Institute of Allergy and Infectious Diseases (NIAID) (HHSN2720002I-FY.2017.B8C12.0080), an institute of the National Institutes of Health (NIH). Similar research is being conducted at other NIAID VTEU sites.
One trial at UMSOM involves healthy volunteers 19 years of age and older; it is the only trial evaluating the vaccine in elderly adults (age 65 years and older). This trial will evaluate different dosages of vaccine with or without an adjuvant, an ingredient used to stimulate better immune responses to a vaccine. The other trial will test the vaccine on adults 19 to 64 when given sequentially or simultaneously with seasonal influenza vaccine. In both these trials, the vaccine was developed by Sanofi Pasteur, based in Lyon, France. The vaccine – called 2017 H7N9 IIV– uses an inactivated form of the H7N9 influenza virus that was collected in 2017 to increase the likelihood that it will provide immunity against a newly evolved strain of the virus. The adjuvant, called AS03, was produced by GSK Biologicals, based in Rockville, MD, USA.
“Vaccine development and testing has been a key part of our research program here at the University of Maryland School of Medicine,” said UMSOM Dean E. Albert Reece, MD, PhD, MBA, Executive Vice President, Medical Affairs, University of Maryland and the John and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. “Influenza vaccine development is important, particularly as new strains arise each year and we face the the risk of potential pandemics.”
CVD researchers are recruiting volunteers for each of the trials. For more information call 410-706-6156 (8 a.m. - 4 p.m.) or visit http://www.medschool.umaryland.edu/CVD/Clinical-Trials-/.
About the University of Maryland School of Medicine
Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with more than half of its academic departments ranked in the top 20 among all public medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/.
About the Center for Vaccine Development
Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. Learn more about the CVD.